You are here

Article Text

Article menu
Download PDFPDF
Poster exhibition Day 2
P126 Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: systematic review and metanalysis
  1. F Guida1,2,
  2. A Fagotti1,2,
  3. A Grossi3,4,
  4. C Vascone1,2,
  5. N Bizzarri1,2,
  6. V Ghirardi1,2,
  7. S Boccia3,4 and
  8. G Scambia1,2
  1. 1Università Cattolica del Sacro Cuore, Istituto di Clinica Ostetrica e Ginecologica
  2. 2Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, U.O.C. di Ginecologia Oncologica
  3. 3Università Cattolica del Sacro Cuore, Sezione di Igiene, Istituto di Sanità Pubblica
  4. 4Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Igiene Ospedaliera, Roma, Italy

Abstract

Introduction/Background Two randomized controlled trials on the role of secondary cytoreductive surgery in platinum-sensitive Recurrent Ovarian Cancer (ROC) patients have shown contrasting results in terms of PFS and OS. Even more debated is the role of surgery in the tertiary setting. This study aims to investigate the current literature on tertiary cytoreductive surgery (TCS) in ROC and to perform a meta-analysis to examine the impact of optimal and sub-optimal TCS on survival.

Methodology A systematic literature review was performed. PubMed, Scopus and Web of Science were searched to retrieve studies published in English and Italian up to 31st March 2019. Quantitative data were pooled out to compare interventions through a meta-analysis. PRISMA statement was used for reporting.

Results Literature search led to 706 records. Of 29 full-text articles obtained after deduplication and screening, 17 were excluded as they didn’t meet eligibility criteria. The remaining 12 studies were all retrospective. The majority had small size cohorts, and a wide heterogeneity in outcome measures and number and type of covariates was observed. Five studies were eligible for meta-analysis, including a total of 694 patients. Overall pooled HR comparing optimal/complete versus suboptimal/partial cytoreduction was 3.17 (CI95: 1.90–5.29; p<0.001) with moderate heterogeneity (I 2: 56.2%; p=0.058), suggesting a protective effect of optimal TCS. Pooled HR for studies considering Disease Specific Survival, comparing residual tumor (RT) <0.5 cm versus >0.5 cm after TCS, was 3.29 (CI95: 1.88–5.73; p<0.001) with low heterogeneity (I 2: 17.4%; p=0.271). Pooled HR for studies considering Overall Survival, comparing RT <0. versus >0 after TCS, was 3.29 (CI95: 1.88–5.73; p <0.001) with very high heterogeneity (I 2: 80.1%; p=0.025).

Conclusion Our data suggests surgery might play a major role in improving survival of patients with ROC in tertiary setting. Nevertheless, the topic remains under-investigated and further studies are needed.

Disclosure Nothing to disclose.

View this table:
Abstract P126 Table 1

Characteristics of the included studies - part 1

View this table:
Abstract P126 Table 2

characteristics of the included studies - part 2

Abstract P126 Figure 1
Abstract P126 Figure 1

Overall analysis (all outcomes included)

https://doi.org/10.1136/ijgc-2019-ESGO.189

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.